Comparative study of the clinical efficacy of the first domestic bioanalogue of tocilizumab based on the results of a randomized clinical trial of phase III

Comparative study of the clinical efficacy of the first domestic bioanalogue of tocilizumab based on the results of a randomized clinical trial of phase III

The article discusses the results of a comparative phase III clinical trial of the efficacy and safety of the biosimilar Complarate (CPR; JSC Generium, Russia) and the reference drug Actemra (ACT; F. Hoffmann-La Roche Ltd., Switzerland) to assess their equivalence in patients with rheumatoid arthrit...

Full description

Saved in:
Bibliographic Details
Main Authors: E. V. Akatova, Yu. S. Bakhareva, O. V. Bugrova, I. B. Vinogradova, E. V. Gerasimova, Yu. E. Drevina, O. B. Ershova, E. V. Zonova, Yu. I. Ivanova, E. P. Ilivanova, M. M. Kostik, D. G. Krechikova, D. A. Kusevich, A. L. Maslyansky, A. D. Meshkov, N. S. Mosesova, K. A. Nagornova, D. V. Nosovich, S. A. Polyakova, T. A. Popova, E. A. Smolyarchuk, V. N. Sorotskaya, Yu. G. Shvarts, L. N. Shilova, M. S. Shostak, I. Yu. Yunonin, N. E. Akhtyamova-Givirovskaya, R. A. Khamitov, O. A. Markova, E. I. Zagoruiko, E. V. Zuev
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2024-12-01
Series:Современная ревматология
Subjects:
tocilizumab
rheumatoid arthritis
acr
das28
clinical disease activity index (cdai)
simplified disease activity index (sdai)
monoclonal antibody
interleukin-6
randomized trial
biosimilar
Online Access:https://mrj.ima-press.net/mrj/article/view/1664
Tags: Add Tag
No Tags, Be the first to tag this record!
Login for hold and recall information

Internet

https://mrj.ima-press.net/mrj/article/view/1664

Similar Items